Sanofi-Aventis has created the third largest generics company in Europe after re-branding its generic operations under the name Zentiva.
By unifying the Group’s generic activities under the Zentiva brand, Sanofi-Aventis has allegedly created the fastest growing generics company in Europe with the ability to provide medicines to 800 million people in Europe, Russia and Turkey.
“Generics are an increasingly important part of Sanofi-Aventis’ plans to become a diversified global healthcare company focused on patients’ needs,” said Belen Garijo, senior vice president, global operations, head of region Europe for Sanofi-Aventis.
The Zentiva brand was chosen based on its success in Central and Eastern Europe as well as its positive reputation in terms of providing support and services to its key customers. The single brand for the business should present a more consistent and high quality image across all the target markets, the company said.
Zentiva, headed by president Rob Koremans, has a product portfolio of more than 350 medicines in therapeutic areas such as cardiovascular, gastro-intestinal, urology, female health, anti-infectives, pain and CNS.
The company said it intends to grow its product line-up and build its position in Europe.
